Forum Discussion
Two steps forward, one step back – news on access to CDKs in second line treatment
Hello everyone,
BCNA has an update on access to CDKs as
second line treatment. Pfizer have this week advised BCNA about a new capped access
program for the CDK inhibitor palbociclib (lbrance) wh...
Really well thank you @arpie. As mentioned above, with the capped access program, from 1st October, you have to pay the $40,000 no matter what. There was a small window of opportunity to enrol for the Palbociclib and AI. My oncologist just made it. I am now just waiting for my pharmacist to obtain the Palbociclib.
So, now I just have to wait and see if I have any side effects. I am also taking Letrozole which I tolerate well.
So, now I just have to wait and see if I have any side effects. I am also taking Letrozole which I tolerate well.